Catalytic Enantioselective Synthesis of 4-Amino-5-aryltetrahydro-1H-benzo[c]azepines by an Aminoarylation Reaction

Abstract

A one-pot asymmetric aminoarylation reaction has been executed for the synthesis of trans-4-amino-5-aryltetrahydrobenzo[c]azepines with excellent diastereo- and enantioselectivity (dr > 99: 1; ee ≤97%). The reaction progresses through aziridination of prochiral N-tosyl-N-cinnamylbenzylamines, followed by an intramolecular 7-endo-tet Friedel–Crafts cyclization of the tethered aziridines generated in situ, where the combination of Cu(OTf)₂ as a catalyst and PhINNs as a nitrene source was found to be effective. A chiral indenyl bis(oxazoline) was shown to be an efficient ligand for the catalytic enantioselective version of this one-pot transformation. This 7-endo-tet cyclization is contrary to the Baldwin cyclization rules.

Key words

tetrahydrobenzazepines - asymmetric catalysis - aminoarylation - aziridines - Friedel–Crafts reaction - endo-tet cyclization

Publikationsverlauf

Eingereicht: 26. Mai 2022

Angenommen nach Revision: 28. Juli 2022

Accepted Manuscript online:
28. Juli 2022

Artikel online veröffentlicht:
23. September 2022

• References and Notes

• 1 Present address: Department of Chemistry, Bidhan Chandra College, Asansol–713304, India
• 2a Xia W, Spector S, Hardy L, Zhao S, Saluk A, Alemane L, Spector NL. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 7494
• 2b Spector S, Spector NL. US 6277844, 2001
• 2c Al-Qawasmeh RA, Lee Y, Cao M.-Y, Gu X, Viau S, Lightfoot J, Wright JA, Young AH. Bioorg. Med. Chem. Lett. 2009; 19: 104
• 2d Keller L, Beaumont S, Liu J.-M, Thoret S, Bignon JS, Wdzieczak-Bakala J, Dauban P, Dodd RH. J. Med. Chem. 2008; 51: 3414
• 2e Pons V, Beaumont S, Tran Huu Dau ME, Iorga BI, Dodd RH. ACS Med. Chem. Lett. 2011; 2: 565
• 2f Zhan G, Zhou J, Liu R, Liu T, Guo G, Wang J, Xiang M, Xue Y, Luo Z, Zhang Y, Yao G. J. Nat. Prod. 2016; 79: 760
• 2g Scott LJ, Goa KL. Drugs 2000; 60: 1095
• 2h Grunewald GL, Dahanukar VH, Criscione KR. Bioorg. Med. Chem. 2001; 9: 1957
• 2i Grunewald GL, Caldwell TM, Li Q, Criscione KR. J. Med. Chem. 2001; 44: 2849
• 2j Bradshaw B, Evans P, Fletcher J, Lee AT. L, Mwashimba PG, Oehlrich D, Thomas EJ, Davies RH, Allen BC. P, Broadley KJ, Hamrouni A, Escargueil C. Org. Biomol. Chem. 2008; 6: 2138
• 2k Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan C.-K, Haltiwanger RC, Gowen M, Hwang S.-M, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF. J. Med. Chem. 2000; 43: 22
• 2l Clark MT, Chang J, Navran SS, Hoozor-Akbar Hoozor-Akbar, Mukhopadhyay A, Amin H, Feller DR, Miller DD. J. Med. Chem. 1986; 29: 181
• 2m Dalence-Guzman MF, Berglund M, Skogvall S, Sterner O. Bioorg. Med. Chem. 2008; 16: 2499
• 2n Berglund M, Dalence-Guzman MF, Skogvall S, Sterner O. Bioorg. Med. Chem. 2008; 16: 2513
• 3a Tabrizchi R. Curr. Opin. Invest. Drugs (BioMed Cent.) 2008; 9: 301
• 3b Schäfer S, Steioff K, Linz W, Bleich M, Busch AE, Löhn M. Eur. J. Pharmacol. 2004; 484: 361
• 3c Gross O, Koepke M.-L, Beirowski B, Schulze-Lohoff M, Segerer S, Weber M. Kidney Int. 2005; 68: 456
• 4a Burnier M. Curr. Opin. Invest. Drugs (BioMed Cent.) 2001; 10: 1957
• 4b Rossi GP. Cardiovasc. Drug Rev. 2003; 21: 51
• 5a Vandormael B, Fourla D.-D, Gramowski-Voß A, Kosson P, Weiss DG, Schröder OH.-U, Lipkowski A, Georgoussi Z, Tourwé D. J. Med. Chem. 2011; 54: 7848
• 5b Ballet S, Feytens D, Buysse K, Chung NN, Tumati S, Keresztes A, Van Duppen J, Lai J, Varga F, Porreca F, Schiller PW, Vanden Broeck J, Tourwé J. J. Med. Chem. 2011; 54: 2467 ; and references cited therein
• 6a Flynn GA, Giroux EL, Dage RC. J. Am. Chem. Soc. 1987; 109: 7914
• 6b Flynn GA, Beight DW, Huber EW, Bey P. Tetrahedron Lett. 1990; 31: 815
• 6c Warshawsky AM, Flynn GA, Koehl JR, Mehdi S, Vaz RJ. Bioorg. Med. Chem. Lett. 1996; 6: 957
• 6d Le Diguarher T, Ortuno J.-C, Shanks D, Guilbaud N, Pierré A, Raimbaud E, Fauchere J.-L, Hickman JA, Tucker GC, Casara PJ. Bioorg. Med. Chem. Lett. 2004; 14: 767
• 7a Lafemina RL, Young SD. GB 2271566 A, 1992
• 7b Johnson RE, Busacca CA. US 5098901, 1991
• 7c Sherlock MH. US 3225031, 1963
• 7d Sherlock MH. US 3242164, 1966
• 7e Masatoshi B, Kenji M, Yutaka B, Noriyuki I, Mikio H, Hajime F, Eiichi S. JP 5913761, 1984
• 7f Molino BF, Liu S, Sambandam A, Guzzo PR, Hu M, Zha C, Nacro K, Manning DD, Isherwood ML, Fleming KN, Cui W, Olson RE. WO2007011820, 2007
• 7g Gámez-Montaño R, Chávez MI, Roussi G, Cruz-Almanza R. Tetrahedron Lett. 2001; 42: 9
• 8a Kamimura A, Taguchi Y. Tetrahedron Lett. 2004; 45: 2335
• 8b Van den Eynde I, Van Rompaey K, Lazzaro F, Tourwé D. J. Comb. Chem. 2004; 6: 468
• 8c Vieira TO, Alper H. Org. Lett. 2008; 10: 485
• 8d Nandakumar A, Kiruthika SE, Naveen K, Perumal PT. Org. Biomol. Chem. 2014; 12: 876
• 8e Hu Y, Huang H. Org. Lett. 2017; 19: 5070
• 8f Pandey AK, Han SH, Mishra NK, Kang D, Lee SH, Chun R, Hong S, Park JS, Kim IS. ACS Catal. 2018; 8: 742
• 9a Baldwin JE. J. Chem. Soc., Chem. Commun. 1976; 732
• 9b Dumoulin D, Lebrun S, Couture A, Deniau E, Grandclaudon P. Tetrahedron: Asymmetry 2010; 21: 195
• 9c So M, Kotake T, Matsuura K, Inui M, Kamimura A. J. Org. Chem. 2012; 77: 4017
• 9d Allin SM, Towler JM. R, Elsegood MR. J, Saha B, Bulman Page PC. Synth. Commun. 2012; 42: 872
• 9e Quick MP, Fröhlich R, Schepmann D, Wünsch B. Org. Biomol. Chem. 2015; 13: 7265
• 9f Palillero-Cisneros A, Gordillo-Guerra PG, Aparicio-Solano DM, Gnecco D, Mendoza A, Juárez JR, Terán JL. Tetrahedron: Asymmetry 2015; 26: 95
• 10a Evans DA, Faul MM, Bilodeau MT. J. Org. Chem. 1991; 56: 6744
• 10b Evans DA, Faul MM, Bilodeau MT, Anderson BA, Barnes DM. J. Am. Chem. Soc. 1993; 115: 5328
• 10c Evans DA, Faul MM, Bilodeau MT. J. Am. Chem. Soc. 1994; 116: 2742
• 11a Hajra S, Maji B, Sinha D, Bar S. Tetrahedron Lett. 2008; 49: 4057
• 11b Hajra S, Maji B, Mal D. Adv. Synth. Catal. 2009; 351: 859
• 11c Hajra S, Bar S. Chem. Commun. 2011; 47: 3981
• 11d Hajra S, Bar S. Tetrahedron: Asymmetry 2011; 22: 775
• 11e Hajra S, Bar S. Tetrahedron: Asymmetry 2012; 23: 151
• 11f Hajra S, Sinha D. J. Org. Chem. 2011; 76: 7334
• 11g Hajra S, Akhtar SkM. S, Aziz SkM. Chem. Commun. 2014; 50: 6913
• 11h Akhta SkM. S, Bar S, Hajra S. Tetrahedron 2022; 103: 132257

For reviews, see:
• 12a Hu XE. Tetrahedron 2004; 60: 2701
• 12b Singh GS, Sudheesh S, Keroletswe N. ARKIVOC 2018; (i): 50
• 12c Talukdar R, Saha A, Ghorai MK. Isr. J. Chem. 2016; 56: 445

For selected examples see:
• 12d Bhattacharyya A, Shahi CK, Pradhan S, Ghorai MK. Org. Lett. 2018; 20: 2925
• 12e Pradhan S, Chauhan N, Shahi CK, Bhattacharyya A, Ghorai MK. Org. Lett. 2020; 22: 7903
• 12f Tarannum S, Sk S, Das S, Wani IA, Ghorai MK. J. Org. Chem. 2020; 85: 367
• 13 4-Amino-5-aryltetrahydro-2-benzazepines 3b–j; General Procedure A two-necked, 25 mL, round-bottomed flask was charged with the Box ligand (1R,2S)-L6 (0.011 g, 0.03 mmol, 0.12 equiv) and Cu(OTf)₂ (0.009 g, 0.025 mmol, 0.1 equiv). Anhyd CH₂Cl₂ (1.2 mL) was added by syringe, and the resulting mixture was stirred for 30 min at rt. To this solution were added substrate 1 (0.467 g, 1.23 mmol, 5.0 equiv) in CH₂Cl₂ (1.2 mL), PhINNs (0.1 g, 0.24 mmol, 1.0 equiv), and powered 4Å MS (0.2 g) and the mixture stirred at rt under argon. As soon as all the nitrenoid reagents were dissolved, additional Cu(OTf)₂ (0.007 g, 0.01 mmol, 0.1 equiv) was added to the reaction medium, which was then stirred at 35 °C under argon. The reaction, which was completed within 1 h, was quenched by dilution with EtOAc (10 mL). The mixture was then filtered through a short plug of silica gel that was washed with additional EtOAc (10 mL). The filtrate was concentrated by rotary evaporation under reduced pressure to give a crude mass that was purified by flash column chromatography (silica gel, EtOAc–hexane). N-{(4S,5R)-5-Phenyl-2-tosyl-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl}-4-nitrobenzenesulfonamide (3b) White solid; yield: 91% (96% ee); mp 164–166 °C; [α]_D ²⁸ −137 (c 0.30, CH₂Cl₂). HPLC [Daicel Chiralpak IA-3, hexane–EtOAc (60:40), 1.0 mL/min, λ = 254 nm]: t _major = 6.1 min, t _minor = 7.2 min. ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, J = 9.2 Hz, 2 H), 7.62 (d, J = 8.0 Hz, 2 H), 7.52 (d, J = 8.8 Hz, 2 H), 7.34 (d, J = 8.0 Hz, 2 H), 7.27–7.25 (m, 3 H), 7.19–7.17 (m, 3 H), 7.10 (d, J = 6.8 Hz, 4 H), 5.03 (d, J = 9.2 Hz, 1 H), 4.99–4.96 (m, 1 H), 4.34 (d, J = 9.2 Hz, 1 H), 3.86 (d, J = 10.8 Hz, 1 H), 3.24 (dd, J = 10.0, 2.0 Hz, 1 H), 3.18–3.14 (m, 1 H), 2.49 (s, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 150.0, 144.6, 143.8, 140.5, 139.5, 132.9, 129.9, 128.9, 128.6, 128.5, 128.4, 128.3, 128.2, 127.7, 127.4, 127.1, 124.2, 62.9, 62.2, 53.8, 49.4, 21.6. DEPT-135 NMR (100 MHz, CDCl₃): δ = 130.4, 129.4, 129.2, 129.1, 129.0, 128.7, 128.6, 128.1, 127.9, 127.5, 124.6, 63.3, 62.7, 54.2, 49.9, 22.0. ESI-MS: m/z [M + Na]⁺ calcd for C₂₉H₂₇N₃NaO₆S₂: 600.1239; found: 600.1238.